Category: Health Science
-
![Willow Biosciences (WLLW.T) takes the romance (and risk) out of cannabinoid production]()
Willow Biosciences (WLLW.T) takes the romance (and risk) out of cannabinoid production
Willow Biosciences (WLLW.T) is a Canadian biotech company based in Vancouver, BC, that is using “a proprietary yeast strain laboratory process” to produce commercial quantities of CBD and CBG”.
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Heritage Cannabis (CANN.C) acquires Opticann – to create an international medical footprint
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”.
-
![Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling]()
Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…
-
Perimeter Medical Imaging AI: Covering the Margin Calls for Cancer
For the last eight months, the Covid-19 virus has been the centre of attention in the media, the markets, and the medical field. Collectively, countries, government agencies, academic institutions and pharmaceutical companies across the world have poured hundreds of millions into efforts combating the viral outbreak that has left so many countries and populations struggling…
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
Perimeter Medical Imaging AI (PINK.V): They’re not curing cancer here, but they’ll help dig it out..
For the last eight months, the Covid-19 virus has been the center of attention in the media, the markets, and the medical field. Collectively, countries and government agencies, and academia, and pharmaceutical companies, have poured hundreds of millions into efforts combating the plague that has left so many countries and populations struggling, but despite the…
-
PredictMedix: Value Meets Growth
Technology is different from every other sector by virtue of one important factor – it scales. Because technology is scaleable, firms penetrate international markets easily, exercise greater pricing power, and capture bigger margins. Businesses exist to solve problems. In solving problems, they create value. Capturing that value, on the other hand, is independent of how…
-
ImmunoPrecise (IPA.V): when scientific breakthrough is executed strategically
You know what grinds my gears? The fact that investors will happily speculate on Tesla (TSLA.NYSE) stock because they think they understand the automobile market, but won’t attempt to do the due diligence for biotechs because it’s “too hard”.
